• Director

    Steven Hoffmann, MS

    Associate Vice President, Science Partnerships
    Translational Science
    Director, Biomarkers Consortium

    [email protected]
    Read Bio
    – Close

    Steve Hoffmann is an Associate Vice President in Research Partnerships and Director of the Biomarkers Consortium at the Foundation for the National Institutes of Health (FNIH). He provides strategic planning, programmatic management, and research administration of a multi-faceted portfolio of established and emerging projects within the Biomarkers Consortium and Accelerating Medicines Partnership including projects focused on neuroscience, rare diseases, organ toxicity, infectious disease and other autoimmune and inflammatory diseases.

    Steve has a broad background in the academic, government and industry sectors in the field of translational biomarkers, molecular immunology, and precision medicine. Prior to joining FNIH, Steve worked as both a project and product manager, supporting protein diagnostics development at Meso Scale Discovery (MSD). Before MSD, Steve was a scientist in the Transplantation and Autoimmunity Branch of the National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK) and led research efforts utilizing immune depletion and co-stimulatory blockade strategies for human renal and islet cell transplant trials. Steve holds a Master of Science degree in Pathology and Laboratory Medicine from the University of North Carolina at Chapel Hill and a Bachelor of Science degree in Biochemistry and Biophysics from the University of Pittsburgh.

  • Director

    Dana Connors, MS, PMP

    Director, Translational Science
    Cancer
    Associate Director, Biomarkers Consortium

    [email protected]
    Read Bio
    – Close

    Dana E. Connors is the Director for Cancer Research Partnerships at FNIH and supports the Executive Committee for the Biomarkers Consortium. He works with the Cancer team to establish and manage project teams and working groups to facilitate the advancement and execution of innovative cancer research and biomarker development, engages international participation from government, industry, academia, patient-advocacy and private sector organizations on research project design and clinical trial development, and supports strategic planning and symposia development. Before coming to the FNIH he was a Project Manager for the Electronic Data Methods Forum at AcademyHealth and an independent consultant working internationally with health care companies and device manufacturers in marketing, communications and project management. Before his consulting role, Dana worked in marketing and communications management for the biomarker portfolios of Thermo Fisher Scientific and BRAHMS Diagnostics. Dana received his Master of Science from the University of Amsterdam and a Bachelor of Arts from the University of Florida.

Portfolio Leads

  • Director

    James O’Leary, MBA

    Director, Translational Science
    Inflammation and Immunity

    [email protected]
  • Director

    Althea Lang, PhD

    Project Manager, Translational Science
    Cancer

    [email protected]
    Read Bio
    – Close

    Althea Lang is a Scientific Project Manager for Cancer Research Partnerships at the Foundation for the National Institutes of Health. Dr. Lang manages the Biomarkers Consortium Cancer Steering Committee (CSC) and supports projects in development within the CSC.

    Prior to joining FNIH, Dr. Lang was Chief of Staff for Materials Science Research at DuPont and Assistant Director of Education Programs at the American Institute of Physics. Dr. Lang earned her Ph.D. from the University of Pennsylvania in Chemistry developing inhibitors of HIV-1, and served as a Technology Transfer Fellow at the Penn Center for Innovation. She holds a Bachelor of Arts in Chemistry from Swarthmore College.

  • Director

    Melissa Jones Reyes, PhD

    Program Manager, Translational Science
    Metabolic Disorders

    [email protected]
    Read Bio
    – Close

    In her role, Melissa oversees the projects under the Metabolic Disorders Biomarkers Consortium (MDSC) portfolio including biomarker qualification efforts in nonalcoholic steatohepatitis (NASH) and nonalcoholic fatty liver disease (NAFLD), bone quality, heart failure, preeclampsia, and emerging programs in obesity, pulmonary hypertension, maternal health and digital health technologies. She has significant experience managing diverse Life Sciences initiatives supporting a wide range of stakeholders across industry, government, academia and private sector. Prior to joining the FNIH, she was Program Manager for the Laboratories Canada Initiative at Merrick & Company, where she facilitated the functional programming and design efforts for biocontainment laboratories in the greater Ottawa Ontario area. During her diverse career she has managed biomedical research programs, clinical trials and studies, and biosurveillance programs. She holds an MS in Biology from East Carolina University, and a PhD in Cell Biology from the University of Kansas Medical Center. She completed her post-doctoral training at the University of Ottawa, Ontario in Cellular and Molecular Medicine.

Donate

Donate to the FNIH today to support medical research that saves lives

Partner With Us

Work with the FNIH to accelerate medical breakthroughs for patients